NAI, VAI, OAI: What Each FDA Inspection Classification Means

FDA gives every inspection one of three classifications. NAI (No Action Indicated) means no objectionable conditions were found. VAI (Voluntary Action Indicated) means objectionable conditions were found but FDA is not taking regulatory action; the company is expected to fix them. OAI (Official Action Indicated) means the findings are serious enough that FDA recommends regulatory action, and a warning letter, import alert or worse usually follows.

The classification is not written on the Form 483. It is decided afterwards, by FDA staff who review the investigator's report and the company's response, and it typically reaches the company 45 to 90 days after the inspection ends. If you have just received a 483 and are wondering whether it will be VAI or OAI, the answer depends on three things covered below: how serious the observations are, whether they repeat earlier citations, and how well the response holds up. If you are checking a supplier, you can see every past outcome on its page in the FDA facility lookup.

The three classifications side by side

Two things the table hides. A VAI is not a pass: it means FDA found problems and chose not to act yet, and the next investigator will check whether they were fixed. And an OAI is not always a warning letter: FDA can close an OAI with a regulatory meeting or an untitled letter, and a strong 483 response sometimes brings a borderline case down to VAI.

How FDA decides: from Form 483 to classification

1. The inspection closes. If the investigator observed objectionable conditions, they issue a Form 483 at the close-out meeting. Our guide to what a Form 483 is covers the document itself.
2. The company responds. There is no legal requirement, but FDA considers a response received within 15 business days of the 483's issue date before deciding whether to escalate. The response needs root cause, scope, corrective action and evidence for every observation; our piece on Form 483 response strategies goes through each.
3. The investigator writes the Establishment Inspection Report. The EIR is the full narrative of what was inspected, what was found and what was discussed. It carries the investigator's recommended classification. Our guide to FDA EIRs explains what it contains.
4. The district or center reviews. For drugs, CDER's Office of Manufacturing Quality reviews the 483, the EIR and the response, and sets the final classification. Repeat citations and inadequate responses are what move a case from VAI to OAI.
5. The classification is communicated and posted. The company receives it in writing; the FDA Data Dashboard and the facility's inspection record show it. The timing is typically 45 to 90 days, longer for foreign inspections and for cases referred for enforcement.

How often inspections end with a 483

The classification follows the 483, so the volume of 483s is the leading indicator. These are the Form 483s with observation-level detail in the Atlas directory, by year of issue, data through July 2026:

Across the 360 most recently inspected facilities in the directory, 106, or 29%, had a Form 483 as their latest outcome and 254 did not. In other words, roughly seven in ten recent inspections ended without a 483, which is the NAI pool; most of the remaining three in ten become VAI; and OAI is the small slice of those where the observations were serious, repeated, or poorly answered. The 2025 sample of 960 Form 483s shows what the typical VAI candidate looks like: a median of 3 observations, 59% with three or fewer, and only 5% with ten or more.

What an OAI leads to

An OAI classification is the gateway to every formal enforcement tool FDA has for a facility:

The Fresenius warning letters of 2026 show the full path at two facilities: 483s in 2020 and 2021 citing the same section, a 2026 483, a response FDA found inadequate, then the letter. Our analysis of how warning letters affect later inspection outcomes covers what happens at the next inspection after an OAI.

Atlas

See what the FDA knows about your next investigator.

30 minutes with the founder. No pitch deck.

See it live

Why a VAI becomes an OAI next time

The classification of one inspection depends partly on the last one. Three patterns show up again and again in warning letters:

The same section cited twice. A facility cited under 21 CFR 211.192 (investigations) at one inspection and again at the next has told FDA its corrective action did not work. The Melrose Park and Ogden letters both say so in as many words.

A response that fixes the symptom. Retraining the operator for an observation that says the investigation was not thorough. FDA reads the 483 response for scope and root cause, and a response without them is the single most common reason a borderline case goes OAI.

Repeat observations marked on the 483. When the investigator writes "this is a repeat observation", the classification review starts from that line.

The practical defence is knowing your own history before the investigator arrives. Every facility's page in the directory lists its inspections, the regulations cited at each, and the investigators who cited them; the same investigators tend to come back.

How to look up a facility's classification history

Two sources, free:

• FDA Data Dashboard. Search the firm name or FEI number; the inspection list shows the final classification for each inspection, with links to any warning letter or import alert. It carries classifications for inspections FDA has closed, which excludes inspections still under review.
• The Atlas facility page. Every inspection on record with its outcome, the Form 483 observations and the sections they cite, the investigators, and the warning letter if one followed. Start at the facility lookup or the investigator lookup if you know who is coming.

For a supplier audit, pull both: the dashboard for FDA's own classification, the facility page for what was actually cited.

Atlas

FDA Inspection Intelligence Digest

We track every 483, EIR, and warning letter the moment it happens. Get the signals before they hit the FDA website.

Subscribe